Atalanta Sosnoff Capital Has Cut Pfizer (PFE) Stake; Helmerich & Payne (HP) Has 0.93 Sentiment

June 21, 2018 - By Darrin Black

Helmerich & Payne, Inc. (NYSE:HP) Logo

Helmerich & Payne Inc (HP) investors sentiment decreased to 0.93 in Q1 2018. It’s down -0.03, from 0.96 in 2017Q4. The ratio is negative, as 190 investment managers increased or started new holdings, while 205 sold and decreased their holdings in Helmerich & Payne Inc. The investment managers in our database now hold: 101.56 million shares, down from 112.80 million shares in 2017Q4. Also, the number of investment managers holding Helmerich & Payne Inc in top ten holdings increased from 7 to 8 for an increase of 1. Sold All: 37 Reduced: 168 Increased: 115 New Position: 75.

Atalanta Sosnoff Capital Llc decreased Pfizer Inc (PFE) stake by 2.83% reported in 2018Q1 SEC filing. Atalanta Sosnoff Capital Llc sold 18,823 shares as Pfizer Inc (PFE)’s stock declined 3.80%. The Atalanta Sosnoff Capital Llc holds 647,034 shares with $22.96 million value, down from 665,857 last quarter. Pfizer Inc now has $213.28B valuation. The stock increased 0.66% or $0.24 during the last trading session, reaching $36.46. About 20.26M shares traded. Pfizer Inc. (NYSE:PFE) has risen 10.95% since June 21, 2017 and is uptrending. It has underperformed by 1.62% the S&P500. Some Historical PFE News: ; 21/05/2018 – ViiV Healthcare Receives EU Marketing Authorisation for Juluca (dolutegravir/rilpivirine), the First 2-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV; 17/04/2018 – JNJ: NO GENERIC COMPETITION EXEPCTED FOR ZYTIGA IN 2018; 30/05/2018 – TNF Cycling in Psoriatic Arthritis Declines for the Second Year in a Row as Newly Approved Agents Such as Pfizer’s Xeljanz and; 30/05/2018 – Pfizer Closes Above 200-Day Moving Average: Technicals; 10/04/2018 – PFIZER INC – WILL CONDUCT ADDITIONAL ANALYSES ON DATA FROM AXITINIB STUDY; 16/04/2018 – BRISTOL-MYERS SQUIBB – IN PHASE 3 CHECKMATE -214 TRIAL, OPDIVO + YERVOY ALSO DELIVERED DURABLE RESPONSES, WITH HIGHER OBJECTIVE RESPONSE RATE VS SUNITINIB; 23/04/2018 – STAT Plus: Pharmalittle: Fresenius walks away from Akorn deal; FDA bounces a Pfizer biosimilar; 15/05/2018 – PFIZER INC – RETACRIT IS EXPECTED TO BE AVAILABLE IN U.S. AT A SIGNIFICANT DISCOUNT TO CURRENT WHOLESALER ACQUISITION COST OF EPOGEN AND PROCRIT; 03/04/2018 – Pfizer in talks with P&G on sale of its consumer business, though they are far apart on price; 13/04/2018 – EpiPen shortages seen in Canada, UK but U.S. supply intact

Investors sentiment decreased to 0.89 in 2018 Q1. Its down 0.17, from 1.06 in 2017Q4. It dropped, as 70 investors sold PFE shares while 718 reduced holdings. 104 funds opened positions while 595 raised stakes. 4.01 billion shares or 1.39% less from 4.07 billion shares in 2017Q4 were reported. Moreover, Caisse De Depot Et Placement Du Quebec has 0.29% invested in Pfizer Inc. (NYSE:PFE) for 3.32 million shares. Factory Mutual, Massachusetts-based fund reported 3.10 million shares. Beck Mack & Oliver Ltd reported 96,668 shares. Logan Mngmt holds 1.28% or 512,863 shares. Steinberg Asset Mgmt owns 1.17% invested in Pfizer Inc. (NYSE:PFE) for 223,949 shares. Cordasco Financial Net holds 2,171 shares. Daiwa Securities Grp accumulated 0.09% or 311,804 shares. Lodestar Inv Counsel Ltd Liability Corp Il invested in 69,330 shares. 3.47 million were accumulated by Toronto Dominion Natl Bank. California-based Blume Management has invested 0.12% in Pfizer Inc. (NYSE:PFE). Raab Moskowitz Asset Lc has invested 2.48% in Pfizer Inc. (NYSE:PFE). Adirondack Tru owns 19,420 shares or 0.51% of their US portfolio. Peregrine Asset Advisers Inc reported 0.16% of its portfolio in Pfizer Inc. (NYSE:PFE). Bluemountain Cap Mngmt Ltd Liability accumulated 19,510 shares or 0.02% of the stock. Fulton Breakefield Broenniman Ltd reported 299,351 shares.

More important recent Pfizer Inc. (NYSE:PFE) news were published by: which released: “Forget Johnson & Johnson: Here Are 2 Better Dividend Stocks” on June 20, 2018, also published article titled: “Better Buy: Pfizer Inc. vs. Johnson & Johnson”, published: “Pfizer – Still A Hold For The Dividend” on June 08, 2018. More interesting news about Pfizer Inc. (NYSE:PFE) was released by: and their article: “In quest to leapfrog Pfizer, Peninsula vaccine company gets $85 million injection” with publication date: June 07, 2018.

Since February 24, 2018, it had 0 insider purchases, and 13 sales for $18.09 million activity. Dolsten Mikael sold $2.39M worth of stock or 64,587 shares. READ IAN C had sold 132,312 shares worth $4.76M on Tuesday, May 1. SUSMAN SALLY sold $1.24 million worth of stock. $1.52 million worth of Pfizer Inc. (NYSE:PFE) shares were sold by HILL CHARLES H. 9,510 shares valued at $353,677 were sold by LUND-JURGENSEN KIRSTEN on Saturday, February 24. CORNWELL W DON had sold 1,758 shares worth $64,679. 27,323 shares were sold by JOHNSON RADY A, worth $998,666 on Tuesday, March 13.

Atalanta Sosnoff Capital Llc increased Royal Dutch Shell Plc Adr A Sh stake by 52,347 shares to 545,485 valued at $34.81M in 2018Q1. It also upped Tjx Cos Inc New (NYSE:TJX) stake by 11,274 shares and now owns 403,805 shares. Conocophillips (NYSE:COP) was raised too.

Analysts await Pfizer Inc. (NYSE:PFE) to report earnings on August, 7. They expect $0.75 EPS, up 11.94% or $0.08 from last year’s $0.67 per share. PFE’s profit will be $4.39B for 12.15 P/E if the $0.75 EPS becomes a reality. After $0.77 actual EPS reported by Pfizer Inc. for the previous quarter, Wall Street now forecasts -2.60% negative EPS growth.

Among 23 analysts covering Pfizer (NYSE:PFE), 10 have Buy rating, 1 Sell and 12 Hold. Therefore 43% are positive. Pfizer has $54.0 highest and $33.0 lowest target. $40.14’s average target is 10.09% above currents $36.46 stock price. Pfizer had 80 analyst reports since July 29, 2015 according to SRatingsIntel. Jefferies maintained Pfizer Inc. (NYSE:PFE) on Thursday, July 14 with “Buy” rating. The stock has “Neutral” rating by Credit Suisse on Thursday, July 20. The rating was maintained by BMO Capital Markets on Friday, April 28 with “Hold”. The rating was initiated by Societe Generale with “Hold” on Wednesday, April 6. The rating was maintained by Piper Jaffray with “Overweight” on Saturday, September 5. The stock of Pfizer Inc. (NYSE:PFE) earned “Market Perform” rating by Leerink Swann on Monday, May 2. The company was maintained on Wednesday, May 2 by BMO Capital Markets. Morgan Stanley maintained the stock with “Overweight” rating in Wednesday, January 31 report. The firm has “Hold” rating given on Wednesday, August 16 by Jefferies. Piper Jaffray maintained Pfizer Inc. (NYSE:PFE) on Tuesday, October 31 with “Buy” rating.

Analysts await Helmerich & Payne, Inc. (NYSE:HP) to report earnings on July, 26. They expect $0.03 EPS, up 116.67% or $0.21 from last year’s $-0.18 per share. HP’s profit will be $3.27M for 538.33 P/E if the $0.03 EPS becomes a reality. After $-0.05 actual EPS reported by Helmerich & Payne, Inc. for the previous quarter, Wall Street now forecasts -160.00% EPS growth.

Since January 1, 0001, it had 0 insider purchases, and 4 insider sales for $5.10 million activity.

Arosa Capital Management Lp holds 6.53% of its portfolio in Helmerich & Payne, Inc. for 706,472 shares. Oppenheimer & Close Llc owns 92,653 shares or 5.88% of their US portfolio. Moreover, Energy Opportunities Capital Management Llc has 4.54% invested in the company for 85,248 shares. The California-based Beddow Capital Management Inc has invested 3.98% in the stock. Grace & White Inc Ny, a New York-based fund reported 198,637 shares.

Helmerich & Payne, Inc. engages in the contract drilling of gas and oil wells. The company has market cap of $7.03 billion. It provides drilling rigs, equipment, personnel, and camps on a contract basis to explore for and develop gas and oil from onshore areas and from fixed platforms, tension-leg platforms, and spars in offshore areas. It has a 16.07 P/E ratio. The firm operates through three divisions: U.S.

More notable recent Helmerich & Payne, Inc. (NYSE:HP) news were published by: which released: “Jefferies Says Buy Land Drillers Now in Huge Contrarian Call” on June 20, 2018, also with their article: “Jefferies Upgrades Helmerich & Payne (HP) to Buy” published on June 19, 2018, published: “Top Analyst Upgrades and Downgrades: Diamondback Energy, Dr Pepper, Fortinet, KB Home, Netflix, Sirius XM and …” on June 19, 2018. More interesting news about Helmerich & Payne, Inc. (NYSE:HP) were released by: and their article: “Nvidia: The Rally Might Just Be Getting Started” published on June 17, 2018 as well as‘s news article titled: “New Research: Key Drivers of Growth for Columbia Banking System, Helmerich & Payne, Spirit Airlines, Keane Group …” with publication date: June 18, 2018.

Ratings analysis reveals 29% of Helmerich & Payne’s analysts are positive. Out of 7 Wall Street analysts rating Helmerich & Payne, 2 give it “Buy”, 0 “Sell” rating, while 5 recommend “Hold”. The lowest target is $77.0 while the high is $94.0. The stock’s average target of $85.50 is 32.35% above today’s ($64.6) share price. HP was included in 7 notes of analysts from September 6, 2016. The firm earned “Buy” rating on Thursday, September 15 by Argus Research. The stock of Helmerich & Payne, Inc. (NYSE:HP) earned “Buy” rating by SunTrust on Wednesday, January 18. The rating was downgraded by Seaport Global Securities on Thursday, December 1 to “Neutral”. The stock has “Sector Perform” rating by RBC Capital Markets on Friday, December 16. The company was downgraded on Thursday, December 8 by Bank of America. On Tuesday, September 6 the stock rating was upgraded by Morgan Stanley to “Equal-Weight”. The firm has “Mkt Perform” rating given on Friday, December 2 by Bernstein.

Helmerich & Payne, Inc. (NYSE:HP) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Recent Posts